Navamedic (NAVA)

Savepig · august 16, 2024, 11:29am

alcantara20 · august 20, 2024, 9:16am

Etter gjennombruddet for ozempic og wegovy som slankemedisin ser det dårlig ut for mysimba sin fremtid. Nedadgående trend i aksjen siden sist sommer. Kan de andre produktene sørge for å snu det?
Eroxon har vel fått så som så tilbakemeldinger til nå.

TekBot · august 20, 2024, 3:31pm

Navamedic ASA - Mandatory notice of trade

Oslo, August 20, 2024: Agnvicen AB, a closely related party to primary insider
Tony Brejke, COO of Navamedic ASA, has today sold 50.000 Navamedic ASA shares at
an average price of NOK 30,60 per share. See attachment for further details
…

Vis børsmeldingen

about the transaction. Following this transaction, Agnvicen AB holds 757,117
shares in the company.

Rune Wahl, Board member and Primary Insider, has today acquired 50.000 Navamedic
ASA shares at an average price of NOK 30,60 per share. See attachments for
further details about the transaction. Following this transaction, Rune Wahl
holds 50.000 shares in the company.

This release is an announcement issued pursuant to legal information obligations
and is subject of the disclosure requirements pursuant to the Market Abuse
Regulation (MAR) Article 19 no. 3 and section 5-12 of the Norwegian Securities
Trading Act

Kilde

Quadruple · august 20, 2024, 8:23pm

Etter gjennombruddet for ozempic
[/quote]

alcantara20 · august 21, 2024, 10:52am

Dette er vel kun midlertidig inntil produksjonen matcher etterspørselen. Nå kommer også et nytt slankemiddel fra Eli Lilly til Norge som skal være bedre enn både ozempic og wegovy.

TekBot · august 21, 2024, 3:22pm

Navamedic ASA - Mandatory notice of trade

Savepig · august 21, 2024, 6:43pm

Rimelig foruroligende egentlig. Noen som har kontakt med ledelsen som vil høre om bakgrunnen?

Quadruple · august 21, 2024, 8:11pm

Dette er vederlagsaksjer utstedt i oppgjøret for Impolin AB i 2022.
At en del av aksjene gjøres om til cash kan ha sin gode grunn.
De som ble solgt igår ble plukket opp av et styremedlem. Ikke usannsynlig at det samme gjelder de 50.000 idag også?

https://navamedic.com/news/navamedic-asa-completes-acquisition-of-impolin-ab-and-issues-consideration-shares/

Quadruple · august 23, 2024, 10:55am

Positive outlook reinforced by earnings rebound

Navamedic released its 2Q report on August 16th and the results were broadly in line with expectations. The earnings rebound in 2Q was notable with the bottom line recovering from the negative territory primarily due to a milestone fee income. Despite this, the company highlighted the potential for further improvement in the second half of the year, supporting our decision to maintain a positive stance towards the stock following the report. Moreover, we perceive no changes in the investment case and keep an unchanged TP of NOK 46/sh. (Norne idag)

Quadruple · august 27, 2024, 8:24am

Verdt å se. Denne dama snakker klart og tydelig norsk, istedenfor engelsk. En fornøyelse å høre på henne.

Hurum · september 3, 2024, 5:11pm

NAVA CEO på FA TV i dag:

Slankemedisin: – Har endret hvordan markedet fungerer - Finansavisen TV

Quadruple · september 4, 2024, 8:01am

Veldig informativt og vel forberedt intervju med CEO Andreassen.

TekBot · september 9, 2024, 2:04pm

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Oslo, 9 September 2024: The board of directors of Navamedic ASA (the “Company”),
has today, on 9 September 2024, in accordance with the authorisation granted to
it by the general meeting on 4 June 2024, resolved to increase the Company’s
…

Vis børsmeldingen

share capital by NOK 170,200 by issuance of 230,000 new shares, each with a
nominal value of NOK 0.74, in order to facilitate the settlement of exercise of
230,000 share options. The exercise price is NOK 19.00 per share for the 230,000
new shares.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 13,070,454.98, divided into 17,662,777
shares, each with a nominal value of NOK 0.74. The share capital increase will
be registered with the Norwegian Register of Business Enterprises as soon as
practically possible after the share contribution has been fully paid.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic full-service provider of high-quality products to
hospitals and through pharmacies. Navamedic meets the specific needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · september 9, 2024, 2:48pm

Navamedic ASA - Mandatory notification of trade by primary insider

Oslo, 9 September 2024: Reference is made to the stock exchange announcement
published earlier today, on 9 September 2024 by Navamedic ASA (the “Company” or
“Navamedic”), regarding the board of directors’ resolution to increase the
…

Vis børsmeldingen

Company’s share capital with NOK 170,200 by the issuance of 230,000 new shares,
in order to facilitate the settlement of exercise of 230,000 share options in
the Company.

The following primary insiders have today exercised share options:

Kathrine Gamborg Andreassen, CEO of Navamedic, has today, on September 9 2024,
exercised 80,000 share options in the Company under her option agreement from
2020 and subscribed for 80,000 new shares in the Company. Following the option
exercise and subscription of the new shares, Kathrine Gamborg Andreassen holds
771,668 shares and 200,000 options in the Company.

Ole Henrik Eriksen, CBDO of Navamedic, has today, on September 9 2024, exercised
75,000 share options in the Company under his option agreement from 2020 and
subscribed for 75,000 new shares in the Company. Following the option exercise
and subscription of the new shares, Ole Henrik Eriksen holds 575,000 shares and
200,000 options in the Company.

Alexander Lidmejer, Commercial Director of Navamedic, has today, on September 9
2024, exercised 75,000 share options in the Company under his option agreement
from 2020 and subscribed for 75,000 new shares in the Company. Following the
option exercise and subscription of the new shares, Alexander Lidmejer holds
77,400 shares and 200,000 options in the Company.

Please refer to the attached notification of trading for further details.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Quadruple · september 9, 2024, 2:57pm

Exercise pris kr 19,- var utidig lavt. Det er jo en ren gavepakke på ca 10 kroner aksjen pr idag.
Og ingenting å strekke seg etter. Skuffende Kathrine!

Quadruple · september 11, 2024, 7:35am

Dette forklarer nok salget av NAVA-aksjene tidligere i år:

**"De tre oppkjøpstoppene Bård Brath Ingerø (f.v.), Narve Reiten og Terje Bakkens egenkapital i Ingerø Reiten Investment Company er blitt spist opp. Nå er de tvunget til å selge.

Hvis man justerer balansen for kursnedgang i Vow og Vow Green Metals, samt kursoppgang i Observe Medical og nedsalg i Navamedic, viser beregningene at egenkapitalen nå kun utgjør 58 millioner kroner."**

Hurum · september 11, 2024, 4:52pm

Litt mange egg i samme kurv her.

Jeg takker Reiten for stor verdiøkning i Navamedic/Observe i alle fall.

TekBot · september 12, 2024, 10:01am

Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic
pharma company and reliable provider of high-quality products to hospitals and
pharmacies, has partnered with Alex Therapeutics, a digital health provider of
…

Vis børsmeldingen

disease and drug companion apps, to aid in Parkinson’s treatment management. The
app will be developed by Alex Therapeutics to support patients on Flexilev®, a
prescription treatment for Parkinson’s disease.

The new companion app provides medication management support that addresses the
specific needs and challenges of people living with Parkinson’s disease. The app
complements the next generation dose dispenser, OraFID®, containing Flexilev®,
offering a unique combination to support patients to adhere to precise and
individualized treatment regimens.

Parkinson’s disease is a neurodegenerative disorder associated with loss of
motor skills and non-motor functions such as cognitive ability, which can make
it difficult to manage treatments. Digital health tools provide an opportunity
to support patients with functions such as reminders and treatment logs.

“We are excited to collaborate with Alex Therapeutics to enhance the lives of
Parkinson’s patients through the companion app. This partnership not only
reflects our commitment to making the treatment more accessible and manageable,
but also underscores our dedication to easing the burden that patients face in
their day-to-day care,” shares Kathrine Gamborg Andreassen, CEO of Navamedic.

CEO and Founder of Alex Therapeutics, John Drakenberg, states, “We are proud to
partner with Navamedic to bring this tailored solution to the Parkinson’s
community. Our goal is to empower patients to manage their treatments
effectively, for better symptom relief and improved quality of life.”

The companion app is set to be launched in Sweden, Norway and Denmark in the
coming year, with plans for further global expansion.

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). Senidose is a fully owned subsidiary of
Navamedic.
For more information, visit: www.navamedic.com

About Alex Therapeutics

Alex Therapeutics is a digital health company based in Stockholm and Boston that
partners with pharmaceutical companies to support people with treatment and
disease-related mental health challenges through clinically validated companion
apps. Alex Therapeutics specializes in oncology and rare diseases, which
typically entail complex treatment regimes and psychological distress. The
company has a strong regulatory team to support CE and FDA approval as well as
clinical evidence generation for SaMDs.
For more information, visit www.alextherapeutics.com

Media Contacts

Navamedic

Kathrine Gamborg Andreassen,
CEO
kathrine@navamedic.com

Alex Therapeutics

Meera Montan, Director of Growth

meera.montan@alextherapeutics.com

Kilde

TekBot · september 19, 2024, 6:24am

Navamedic ASA - Registration of share capital increase

Oslo, 19 September 2024: Reference is made to the stock exchange announcement
published on 9 September 2024 by Navamedic ASA (the “Company”) regarding the
board of directors’ resolution to increase the Company’s share capital in
…

Vis børsmeldingen

connection with the exercise of employee share options. The share capital
increase pertaining to the exercised share options has now been registered with
the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The new
share capital of the Company is NOK 13,070,454.98, divided into 17,662,777
shares, each with a nominal value of NOK 0.74.

For further information, please contact: Lars Hjarrand, CFO, Navamedic, Mobile:
+47 917 62 842 E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA: Navamedic ASA is a Nordic full-service provider of high
-quality products to hospitals and through pharmacies. Navamedic meets the
specific needs of patients and consumers by leveraging its highly scalable
market access platform, leading category competence and local knowledge.
Navamedic is present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in Oslo,
Norway, and listed on the Oslo Stock Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Savepig · september 30, 2024, 9:20am

Noen som aner om man kan håpe at Q3 blir et sterkt kvartal også i år for Navamedic?

Omsetningen har mer eller mindre tørket ut i denne aksjen, så man har ekstremt liten visibilitet i om markedet priser den korrekt nå.